{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:45:57Z","timestamp":1773531957684,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T00:00:00Z","timestamp":1428537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea","award":["HI14C2003"],"award-info":[{"award-number":["HI14C2003"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","krcp-ksn.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Research and Clinical Practice"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.krcp.2015.03.003","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T13:49:24Z","timestamp":1428760164000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Nonimmunologic targets of immunosuppressive agents in podocytes"],"prefix":"10.1016","volume":"34","author":[{"given":"Tae-Hyun","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.krcp.2015.03.003_bib1","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1046\/j.1523-1755.1999.00408.x","article-title":"Changing patterns in the histopathology of idiopathic NS in children","volume":"55","author":"Bonilla-Felix","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2015.03.003_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","article-title":"Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976\u20131979 and 1995\u20131997","volume":"30","author":"Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.krcp.2015.03.003_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00020.2002","article-title":"Cell biology of the glomerular podocyte","volume":"83","author":"Pavenst\u00e4dt","year":"2003","journal-title":"Physiol Rev"},{"key":"10.1016\/j.krcp.2015.03.003_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00041552-200107000-00009","article-title":"Molecular basis of glomerular permselectivity","volume":"10","author":"Tryggvason","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.krcp.2015.03.003_bib5","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1172\/JCI200523371","article-title":"Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner","volume":"115","author":"Asanuma","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2015.03.003_bib6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00467-009-1425-1","article-title":"Enzymatic disease of the podocyte","volume":"25","author":"Kistler","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ndt\/14.suppl_3.74","article-title":"Treatment of primary focal segmental glomerulosclerosis","volume":"14","author":"Meyrier","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2015.03.003_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1586\/ecp.10.31","article-title":"Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome","volume":"3","author":"Oh","year":"2010","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.krcp.2015.03.003_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrneph.2011.171","article-title":"The podocyte as a target for therapies\u2014new and old","volume":"8","author":"Mathieson","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.krcp.2015.03.003_bib11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/sj.ki.5000341","article-title":"Minimal change nephrotic syndrome and classical Hodgkin\u05f3s lymphoma: report of 21 cases and review of the literature","volume":"69","author":"Audard","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2015.03.003_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","article-title":"Idiopathic nephrotic syndrome and atopy: is there a common link?","volume":"54","author":"Abdel-Hafez","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.krcp.2015.03.003_bib13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1523-1755.2000.00870.x","article-title":"Dominant T cells in idiopathic nephrotic syndrome of childhood","volume":"57","author":"Frank","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2015.03.003_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2249.1995.tb03725.x","article-title":"Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome","volume":"100","author":"Neuhaus","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.krcp.2015.03.003_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1042\/CS20040095","article-title":"Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome","volume":"107","author":"van den Berg","year":"2004","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.krcp.2015.03.003_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy\u2014a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1106215","article-title":"A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis","volume":"308","author":"Winn","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.krcp.2015.03.003_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1681\/ASN.V72290","article-title":"Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy","volume":"7","author":"Ambalavanan","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00866293","article-title":"Effect of cyclosporin A on proteinuria in patients with Alport\u05f3s syndrome","volume":"6","author":"Call\u00eds","year":"1992","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/01.ASN.0000046964.15831.16","article-title":"Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model","volume":"14","author":"Chen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00467-009-1211-0","article-title":"Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation","volume":"24","author":"Malina","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.krcp.2012.10.002","article-title":"Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis","volume":"31","author":"Savin","year":"2012","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.krcp.2015.03.003_bib23","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1681\/ASN.2005020142","article-title":"Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins","volume":"16","author":"Wada","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib24","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1159\/000131892","article-title":"Dexamethasone\u2019s prosurvival benefits in podocytes require extracellular signal-regulated kinase phosphorylation","volume":"109","author":"Wada","year":"2008","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","article-title":"Direct effects of dexamethasone on human podocytes","volume":"70","author":"Xing","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2015.03.003_bib26","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/j.1523-1755.2005.00723.x","article-title":"Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization","volume":"68","author":"Ransom","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2015.03.003_bib27","first-page":"95","article-title":"Levamisole in the adjuvant treatment of colon cancer","volume":"10","author":"Mutch","year":"1991","journal-title":"Clin Pharm"},{"key":"10.1016\/j.krcp.2015.03.003_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S0031182005009108","article-title":"Immunomodulatory effect of various anti-parasitics: a review","volume":"132","author":"Sajid","year":"2006","journal-title":"Parasitology"},{"key":"10.1016\/j.krcp.2015.03.003_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2567.2000.00042.x","article-title":"Levamisole induces interleukin-18 and shifts type 1\/type 2 cytokine balance","volume":"100","author":"Szeto","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.krcp.2015.03.003_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1042\/CS20140749","article-title":"Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into mechanisms of action via direct action on the kidney podocyte","volume":"128","author":"Jiang","year":"2015","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.krcp.2015.03.003_bib31","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","article-title":"Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations","volume":"72","author":"Cattran","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2015.03.003_bib32","doi-asserted-by":"crossref","first-page":"vi79","DOI":"10.1093\/ndt\/gfg1067","article-title":"Treatment of idiopathic nephrosis by immunophillin modulation","volume":"18","author":"Meyrier","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.krcp.2015.03.003_bib33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.krcp.2015.03.003_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/ng1592","article-title":"TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function","volume":"37","author":"Reiser","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.krcp.2015.03.003_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1681\/ASN.2006091010","article-title":"Induction of TRPC6 channel in acquired forms of proteinuric kidney disease","volume":"18","author":"M\u00f6ller","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib36","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.ajpath.2011.06.033","article-title":"Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway","volume":"179","author":"Nijenhuis","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.krcp.2015.03.003_bib37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1042\/cs0820641","article-title":"Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome","volume":"82","author":"Zietse","year":"1992","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.krcp.2015.03.003_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.krcp.2015.03.003_bib39","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","article-title":"Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor","volume":"107","author":"Perosa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.krcp.2015.03.003_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ncpneph0133","article-title":"Drug insight: rituximab in renal disease and transplantation","volume":"2","author":"Salama","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib41","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s00467-005-2013-7","article-title":"Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome","volume":"20","author":"Nozu","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib42","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMc055495","article-title":"Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment","volume":"354","author":"Pescovitz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2015.03.003_bib43","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.krcp.2015.03.003_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1681\/ASN.2013111213","article-title":"Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease","volume":"26","author":"Yoo","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib45","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1517\/14712598.2013.845661","article-title":"T-cell co-stimulatory blockade in transplantation: two steps forward one step back!","volume":"13","author":"Riella","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.krcp.2015.03.003_bib46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","article-title":"Abatacept","volume":"5","author":"Moreland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.krcp.2015.03.003_bib47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1517\/14712598.2014.896332","article-title":"Co-stimulatory blockade with belatacept in kidney transplantation","volume":"14","author":"Chopra","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.krcp.2015.03.003_bib48","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI20402","article-title":"Induction of B7-1 in podocytes is associated with nephrotic syndrome","volume":"113","author":"Reiser","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2015.03.003_bib49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/14712591003596318","article-title":"Galiximab: a review","volume":"10","author":"Bhat","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.krcp.2015.03.003_bib50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3816\/CLM.2008.n.038","article-title":"The use of galiximab in non-Hodgkin lymphoma","volume":"8","author":"Vinjamaram","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.krcp.2015.03.003_bib51","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2015.03.003_bib52","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1126\/science.1065323","article-title":"Lysophospholipids\u2014receptor revelations","volume":"294","author":"Hla","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.krcp.2015.03.003_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbalip.2008.03.001","article-title":"Regulation of the roles of sphingosine 1-phosphate and its type 1 G protein-coupled receptor in T cell immunity and autoimmunity","volume":"1781","author":"Goetzl","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.krcp.2015.03.003_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/01.wnl.0000338569.32367.3d","article-title":"FTY720 D2201 Study Group: Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study","volume":"72","author":"O\u2019Connor","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.krcp.2015.03.003_bib55","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"FTY720 D2201 Study Group: Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.krcp.2015.03.003_bib56","doi-asserted-by":"crossref","first-page":"F1516","DOI":"10.1152\/ajprenal.00311.2005","article-title":"Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney","volume":"290","author":"Awad","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.krcp.2015.03.003_bib57","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/ki.2010.544","article-title":"Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes","volume":"79","author":"Awad","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.krcp.2015.03.003_bib58","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1073\/pnas.92.17.7839","article-title":"The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin","volume":"92","author":"Schwecke","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.krcp.2015.03.003_bib59","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.krcp.2015.03.003_bib60","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1172\/JCI57935","article-title":"The targeted podocyte","volume":"121","author":"Fogo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2015.03.003_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.freeradbiomed.2013.05.014","article-title":"Cellular metabolic and autophagic pathways: traffic control by redox signaling","volume":"63","author":"Dodson","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.krcp.2015.03.003_bib62","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/db13-1279","article-title":"Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy","volume":"63","author":"Zhang","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.krcp.2015.03.003_bib63","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice","volume":"121","author":"Inoki","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2015.03.003_bib64","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice","volume":"121","author":"G\u00f6del","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.krcp.2015.03.003_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trre.2011.10.003","article-title":"mTOR inhibitor-associated proteinuria in kidney transplant recipients","volume":"26","author":"Diekmann","year":"2012","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.krcp.2015.03.003_bib66","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.krcp.2015.03.003_bib67","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: from models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J Clin Invest"}],"container-title":["Kidney Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211913215000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211913215000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T22:50:19Z","timestamp":1651704619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211913215000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S2211913215000327"],"URL":"https:\/\/doi.org\/10.1016\/j.krcp.2015.03.003","relation":{},"ISSN":["2211-9132"],"issn-type":[{"value":"2211-9132","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonimmunologic targets of immunosuppressive agents in podocytes","name":"articletitle","label":"Article Title"},{"value":"Kidney Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.krcp.2015.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Korea LLC.","name":"copyright","label":"Copyright"}]}}